Zoetis Inc. (NYSE:ZTS) Shares Sold by Equitable Trust Co.

Equitable Trust Co. reduced its stake in shares of Zoetis Inc. (NYSE:ZTS) by 1.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 24,705 shares of the company’s stock after selling 488 shares during the period. Equitable Trust Co.’s holdings in Zoetis were worth $4,025,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Darwin Wealth Management LLC acquired a new position in shares of Zoetis during the 3rd quarter worth approximately $31,000. First Personal Financial Services acquired a new position in shares of Zoetis during the 3rd quarter worth approximately $33,000. Capital Performance Advisors LLP acquired a new position in shares of Zoetis during the 3rd quarter worth approximately $33,000. Dunhill Financial LLC boosted its holdings in shares of Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after purchasing an additional 75 shares during the last quarter. Finally, Fortitude Family Office LLC boosted its holdings in shares of Zoetis by 1,387.5% during the 3rd quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock worth $46,000 after purchasing an additional 222 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently weighed in on ZTS shares. UBS Group assumed coverage on Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 target price on the stock. Leerink Partners assumed coverage on shares of Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. Morgan Stanley reduced their price target on shares of Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Stifel Nicolaus reduced their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Zoetis presently has a consensus rating of “Buy” and an average target price of $215.00.

Zoetis Stock Performance

NYSE:ZTS opened at $171.37 on Monday. The company has a fifty day simple moving average of $169.26 and a two-hundred day simple moving average of $179.22. The company has a market cap of $77.32 billion, a price-to-earnings ratio of 32.21, a price-to-earnings-growth ratio of 2.77 and a beta of 0.90. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.53.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.17%. Zoetis’s dividend payout ratio (DPR) is 37.59%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.